Amgen, Inc. (AMGN)’s Drug Trial Fails To Live Up To Expectation

Shares of Amgen, Inc. (NASDAQ:AMGN), which are up almost 16% this year, were trending high in the early afternoon hours, gaining nearly 4% after a day that saw them topple following negative study results. It appears as though investors are now less concerned about the failed trail because the company said the positive results obtained earlier this month would be sufficient to support submissions for regulatory approvals around the world. On CNBC, Yaron Werber, senior biotech analysts at Citi Investment Research, weighed in on the failed study and what lies ahead for the company.

Amgen, Inc. (NASDAQ:AMGN)

Amgen, Inc. (NASDAQ:AMGN) reported that a study of its drug Kyprolis, for a type of blood cancer, failed to help patients live longer compared to the standard care. The study focused on patients with an advanced case of the blood cancer condition known as multiple myeloma. The drug is approved in the U.S., but the company needed survival evidence to obtain approval in Europe.

Coming on to the case of Amgen, Inc. (NASDAQ:AMGN) and the failure of Kyprolis to improve survival rates, Werber said all is not lost for the company because it already has study results that are good enough for approval.

“This is one of the main reasons why Amgen quite earned it. To put it into perspective, they’ve had another study that was successful recently for the drug that will get approved. But overall, if you look at the profile of this drug Kyrolis  myeloma, which is a blood cancer, the overall profile is probably not quite with originally expected, and we think maybe numbers are going to come down,” he said.

He also talked about Amgen, Inc. (NASDAQ:AMGN)’s journey into developing treatment for myeloma and the marketing opportunity for Kyrolis. He noted that the market is there, but the challenge is that patients keep advancing to better drugs that can keep them alive.

“The market is sizable and continues to grow, and as you know, unfortunately, patients with cancer die, and they always progress from one drug to the next [...],” said Werber.

Disclosure: none

blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

10 Most Influential Papers In Economics

Top 8 Biggest Charities in the US

10 Worst Celebrity Career Moves Ever

Top 10 Best Paid Tennis Stars in the World

10 Cities with High Demand for Nurses

6 of the Worst Greeting Card Messages Ever Crafted

6 Ways to Make Money in ArcheAge and Build Your Empire

10 Foods To Eat To Lower Cholesterol Levels

The 10 Most Hated Television Characters of All Time

The 30 Worst Halloween Costume Ideas Ever Brought to Horrible Life

10 Vocational Skills in Demand Today with Jobs Waiting to be Filled

10 Best Places to Visit in Central and South America

The 10 Greatest Empires in History Which Nearly Conquered the World

The 6 Cheapest Boarding Schools In America 2015

5 Clear Reasons LoL is Better than DotA, Continues to Rule MOBAs

The Only 9 Teams with a Chance to Win the Super Bowl

The 15 Most Common Phobias in America that Induce Fits of Panic

Top 6 Least Expensive Tourist Destinations in 2014

Jim Goetz, Peter Fenton, Jim Breyer: Top 6 Venture Investors for 2014

Top 15 Billionaires in 2014

5 Pitfalls To Avoid When Buying a Franchise

Top 20 Medical Schools in the US – 2014 Rankings

4 Business Strategies that Turned Jamie Oliver into the World’s Richest Chef

6 Qualities That Make You A Good Team Player

10 High Paying Seasonal Jobs in America this Holiday Season

The 10 Busiest Shipping Lanes in the World

5 Most Valuable Brands in China

The 10 States with Highest Substance Abuse Rates Crippling Their Populace

The Top 10 Things to Do Before You Die That Will Echo for Eternity

The 10 Best Selling Items on Etsy

Top 10 Things to Do in Tokyo, the Greatest City in the World

10 Mistakes on Social Media that Can Harm You and Will Probably Get You Canned

The 10 Best Cities to Find Jobs in 2014

The 10 Most Controversial Songs Of All Time to Hit (and get Banned from) the Airwaves

The 20 Biggest IPOs in US History

The 10 Best Places to Visit in Mexico that Are Beautiful and Safe

7 Bad Habits that Age You Beyond Your Years

The 40 Best Fortune Cookie Sayings That Will Leave You Bemused, Befuddled, or Beguiled

10 Foods to Eat Before a Workout to Make Every Drop of Sweat Count

The 5 Best Documentaries On Netflix You Must See

The Most Heartwarming and Inspirational Story Of This Halloween Season, It Will Make You Cry and Jump For Joy

10 Best Party Songs of All Time to Bring the House Down With

5 New World Order Conspiracy Theories that Will Strangle the World

The 10 Highest Rated Movies of 2014

The 10 Largest Container Shipping Companies in the World

The 10 Largest Armies in the World: Who Should We Be Afraid Of?

Best Warren Buffett Quotes on Money You Need to Hear

The 10 Highest Suicide Rates by Profession

The 20 Most Underrated Movies of All Time

The 10 Fastest Growing Companies in America

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!